Offices of Drug Evaluation Deputy Directors
Executive Summary
FDA has named deputies for each of its five drug review offices: Division of Anti-viral Drug Products' Rachel Berman, MD, (ODE I); Center for Devices & Radiologic Health Mammography Quality & Radiation Programs Division Deputy Director Florence Houn, MD, (ODE II); Medical Imaging & Radiopharmaceutical Drug Products Division Deputy Director Victor Raczkowski, MD, (ODE III); Reproductive & Urologic Drug Products Division Medical Officer Sandra Kweder, MD, (ODE IV); and Oncology Drug Products Division Director Robert Delap, MD, (ODE V)
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth